Provided by Tiger Trade Technology Pte. Ltd.

LUCID DIAGNOSTICS INC.

0.7829
-0.0212-2.64%
Post-market: 0.78750.0046+0.59%19:30 EDT
Volume:1.22M
Turnover:974.80K
Market Cap:159.12M
PE:-1.70
High:0.8560
Open:0.8480
Low:0.7800
Close:0.8041
52wk High:1.63
52wk Low:0.7800
Shares:203.24M
Float Shares:152.47M
Volume Ratio:1.05
T/O Rate:0.80%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4616
EPS(LYR):-0.6922
ROE:-556.27%
ROA:-81.62%
PB:14.56
PE(LYR):-1.13

Loading ...

Lucid Diagnostics (LUCD) Receives a Buy from Maxim Group

TIPRANKS
·
Aug 14

Press Release: PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results

Dow Jones
·
Aug 14

Lucid Diagnostics Reports Q2 Growth Ahead of Medicare Decision

TIPRANKS
·
Aug 13

PAVmed Subsidiary Lucid Diagnostics Posts 2Q Revenue of USD 1.5 Million

Reuters
·
Aug 13

Press Release: Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results

Dow Jones
·
Aug 13

Lucid Diagnostics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 13

Lucid Diagnostics Inc: Qtrly REV $1.5 Mln, EPS $-0.08 - SEC Filing

THOMSON REUTERS
·
Aug 13

Lucid Diagnostics Q2 FY26 Revenue Rises 25% to USD 1.5 Million

Reuters
·
Aug 13

Lucid Diagnostics Inc Expected to Post a Loss of 7 Cents a Share - Earnings Preview

Reuters
·
Aug 11

PAVmed Unit Lucid Diagnostics Wins Concert Commercial Coverage Policy for EsoGuard Test

Reuters
·
Aug 05

Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for Its Esoguard® Esophageal DNA Test

THOMSON REUTERS
·
Aug 05

Lucid Diagnostics to Present at Needham, Canaccord Investor Conferences

Reuters
·
Aug 04

Lucid Diagnostics Management Participates in Canaccord Genuity Growth Conference Fireside Chat

Reuters
·
Aug 04

Lucid Diagnostics Schedules Business Update Call to Discuss Q2 2026 Results

Reuters
·
Jul 30

Lucid Diagnostics Shareholders Approve Stock Authorization Increase

TIPRANKS
·
Jun 25

Lucid Diagnostics Shareholders Approve Charter Amendment Raising Authorized Common Shares to 400 Million

Reuters
·
Jun 25

Lucid Diagnostics director Dennis Matheis acquires 245,000 common shares for $245,270.00

Reuters
·
May 22

PAVmed Q1 FY26 net loss widens to $7 million; operating expenses rise to $8.1 million

Reuters
·
May 15

Press Release: PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results

Dow Jones
·
May 15

Press Release: Lucid Diagnostics Provides Business Update and Reports First Quarter 2026 Financial Results

Dow Jones
·
May 14